GlassScriptPhysician profile
Salvatore L Grimaldi
NPI 1083735401
$310,103.46
in general payments reported to CMS, 2019-2025
23 companies · $167K in 2025
The $167K reported for 2025 was more than what 99% of Facial Plastic Surgery providers received nationally (typical 2025 total: $271).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,058 · 2020: $210 · 2021: $688 · 2022: $688 · 2023: $652 · 2024: $140K · 2025: $167K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $166K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $140K · Food and Beverage: $2,107 · Education: $57.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $165,709.12 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $139,585.00 |
| Food and Beverage | $2,106.83 |
| Education | $57.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philadelphia Medical Management Company LLC | $305,294.12 | 2024-2025 | |
| Medtronic, INC. | $971.93 | 2021-2025 | Propel, Sinuva, Stealthstation S8 Platform |
| Regeneron Healthcare Solutions, INC. | $762.63 | 2019-2025 | Dupixent |
| Optinose US, INC. | $720.28 | 2019-2025 | |
| Intersect Ent, INC. | $600.66 | 2019-2022 | |
| Glaxosmithkline, LLC. | $245.53 | 2021-2025 | Nucala |
| Genzyme Corporation | $238.90 | 2019-2025 | |
| Acclarent, INC | $229.49 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $189.52 | 2021-2025 | Hyqvia |
| Stryker Corporation | $162.30 | 2021-2022 | |
| Neurent Medical Limited | $140.68 | 2023 | Neuromark Device, Neuromark Radiofrequency Console |
| Aerin Medical INC. | $124.07 | 2019-2023 | |
| Alk-Abello, INC | $75.09 | 2019-2021 | |
| Kaleo, INC. | $68.81 | 2019-2021 | |
| Shire North American Group INC | $61.11 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $41.92 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $37.21 | 2021-2023 | |
| Smith+Nephew, INC. | $33.37 | 2019 | |
| Phadia US INC. | $28.11 | 2024 | Immunocap |
| Ars Pharmaceuticals Operations, INC. | $21.71 | 2025 | Neffy |
| Hikma Pharmaceuticals USA | $19.42 | 2024 | Ryaltris |
| Coopersurgical, INC. | $18.95 | 2025 | Onetrac Lx |
| Novartis Pharmaceuticals Corporation | $17.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,900,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salvatore Grimaldi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.